ClinicalTrials.gg
CompletedNCT01275222Updated Jun 25, 2021Results posted

Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors

A Phase 1/2 interventional study of RAD001 and Imatinib 600mg/day (Glevec is the brand name for imatinib) in Gastrointestinal Stromal Tumors, sponsored by Novartis Pharmaceuticals. Completed at 16 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-25.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 8 years 1 month after the study started (first participant enrolled Nov 2002, registered Jan 2011).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
117
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies in Gastrointestinal Stromal Tumors by Novartis — none open to participants now, none under way, none of them phase 3. Gastrointestinal Stromal Tumors · Novartis.

Enrollment
10th of 26
117 · median 76
Started
2002
with 2 others
Phase 1/2
Only one
of the 27
Registered
17th of 27
by date

Among the 27 studies in Gastrointestinal Stromal Tumors by Novartis, this one is the 10th largest by enrollment of the 26 interventional ones that give a count, is one of 3 that started in 2002, is the only one in phase 1/2, and was the 17th registered.

Gastrointestinal Stromal Tumors

343 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 61 are open to participants now.

Browse Gastrointestinal Stromal Tumors studies →

Open to participants now

None of the 27 studies in Gastrointestinal Stromal Tumors by Novartis is open now. The open studies under Gastrointestinal Stromal Tumors, anywhere →

Who these studies take

Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 27 studies in Gastrointestinal Stromal Tumors by Novartis as a file.
02

Study summary

This trial was a Phase I/II, non-randomized, open label, multi-center study, following a sequential 2-part design.

Read the detailed description

The first part, Phase I, was designed to assess whether there is a pharmacokinetic interaction between Glivec/Gleevec (imatinib) and RAD001(everolimus) as well as to collect safety data when these two drugs are co-administered. The second part, (Phase II), was designed to assess the potential efficacy of the combination in imatinib-resistant GIST patients in two strata of patients:

  • Patients resistant to imatinib as first-line drug therapy and in whom the maximum tolerated dose was at least 600 mg/d (Stratum 1, first-line resistant/refractory)
  • Patients resistant to imatinib as well as to post-imatinib drug therapy (Stratum 2, post second-line therapy).

It was decided to discontinue the study and close to further enrollment based on alternative treatment options that became available. Phase 1 and Phase 2 Stratum 1 were ended early on 02-Nov-2006. Investigators were allowed to complete the enrollment in the Phase 2 Stratum 2.

03

Conditions studied

  • Gastrointestinal Stromal Tumors

Keywords

  • RAD001
  • everolimusGIST
  • everolimus
  • mTOR
  • Imatinib resistant
  • Imatinib-refractory/resistant
  • gastrointestinal stromal tumors
  • Gastrointestinal Stromal Tumors(GIST)
  • soft tissue sarcoma
  • stomach tumor
  • tumor of interstitial cells of Cajal (ICC)
  • digestive system cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Phase l:

  • Patients aged ≥ 18 years
  • Patients with a proven diagnosis of GIST and clinical evidence of resistance to imatinib despite at least 4 months continuous treatment with imatinib
  • Patients with at least 2 months at a dosage of ≥ 600 mg/day (progression despite uninterrupted therapy for 2 months at ≥800 mg/d for patients entering the Phase I cohort investigating the 800 mg/d dose)
  • Patients were to have at least one (longest diameter ≥20 mm on conventional CT or MRI scan
  • patients were to have ≥10 mm on spiral CT) and were to have a Score ≤ 2.
  • Patients also were to have adequate bone marrow, liver and renal function on imatinib treatment, as specified in the protocol

Phase ll:

  • For Phase II (Stratum 2) patients must have progression on other drug therapies following prior progression on imatinib (Stratum 2)

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or breast-feeding
  • Patients presenting with known or symptomatic or
  • Patients with any concurrent major medical condition liable to compromise the patient's participation in the study (e.g. known infection, uncontrolled diabetes, serious cardiac dysrhythmia or condition, classification of III or IV, congestive cardiac failure, myocardial infarction with 6 months, unstable angina, chronic or acute renal or liver disease, uncontrolled infections including abscess or fistulae, etc.)
  • Patients with a history of another within 5 years prior to study entry, except curatively treated non-melanotic skin cancer or in-situ cervical cancer
  • Patients unwilling to or unable to comply with the protocol
  • Patients who are receiving (only if the p70s6 kinase1 assay is being performed), since these have been shown to inhibit p70s6 kinase1 activity.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
117 participants (actual)

Study arms

  • Experimental
    Phase l: RAD001 20mg/week

    RAD001 20 mg was given once a week.

    Drug: RAD001

  • Experimental
    Phase l: RAD001 2.5mg/day + Glivec 600mg/day

    RAD001 2.5 mg was given in combination with Glivec/Gleevec 600mg/day.

    Drug: RAD001 · Drug: Imatinib 600mg/day (Glevec is the brand name for imatinib)

  • Experimental
    Phase l: RAD001 5mg/day + Glivec 600mg/day

    RAD001 5 mg was given in combination with Glivec/Gleevec 600mg/day.

    Drug: RAD001 · Drug: Imatinib 600mg/day (Glevec is the brand name for imatinib)

  • Experimental
    Phase l: RAD001 2.5mg/day + Glivec 800mg/day

    RAD001 2.5 mg was given in combination with Glivec/Gleevec 800mg/day.

    Drug: RAD001 · Drug: Imatinib 600mg/day (Glevec is the brand name for imatinib)

  • Experimental
    Phase ll - Stratum l (first-line resistant/refractory): RAD001 2.5mg/day + Glivec 600mg/day

    All first-line resistant/refractory patients received RAD001 2.5mg/day in combination with Glivec/Gleevec at a dose of 600mg/day.

    Drug: RAD001 · Drug: Imatinib 800mg/day (Glevec is the brand name for imatinib)

  • Experimental
    Phase ll - Stratum ll: (post second-line therapy): RAD001 2.5mg/day + Glivec 600mg/day

    All post-second-line patients received RAD001 2.5mg/day in combination with Glivec/Gleevec at a dose of 600mg/day

    Drug: RAD001 · Drug: Imatinib 800mg/day (Glevec is the brand name for imatinib)

Interventions

  • DrugRAD001

    RAD001 was in tablets of 0.5 mg, 1.0 mg, 2.5 mg and 5.0 mg strength and was taken by mouth, once a week or once a day depending upon the treatment group the patient was enrolled into.

    Also known as: everolimus

  • DrugImatinib 600mg/day (Glevec is the brand name for imatinib)

    Drug page: Imatinib

    Glivec/Gleevec was supplied as commercialized 100 mg and 400 mg tablets. Gleevec/Glivec was provided as capsules of 100 mg strength in bottles containing 60 capsules each. The use of this supply was study center specific. Glivec/Gleevec was taken, by mouth, at a dose of 300 mg twice a day. The Glivec/Gleevec regimen was changed from 600 mg once a day to 300 mg BID, by an amendment since taking too many tablets at once was difficult for patients with gastro-intestinal disease. In the phase II part of the study all patients received Glivec 600 mg/day.

    Also known as: STI571

  • DrugImatinib 800mg/day (Glevec is the brand name for imatinib)

    Drug page: Imatinib

    Glivec/Gleevec was supplied as commercialized 100 mg and 400 mg tablets. Gleevec/Glivec was provided as capsules of 100 mg strength in bottles containing 60 capsules each. The use of this supply was study center specific. Glivec/Gleevec was taken, by mouth. In the phase II part of the study all patients received Glivec 600 mg/day, except for 2 patients who received Glivec at a dose of 800 mg/day. This dose was permitted in Phase II as it was found to be safe in Phase I.

    Also known as: STI571

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs): Phase I & II

    Assessed safety and tolerability of the combination administration of RAD001 and imatinib when given to patients with imatinib-refractory gastro-intestinal stromal tumors (GIST) by number of participants with adverse events.

    Time frame: 4 - 8 weeks

  2. Best Overall Response (BOR) as Assessed by Overall Response (Complete Response (CR) & Partial Response (PR)) - Phase I & II

    Assessed clinical efficacy of the combination regimen in this patient population per BOR by Overall response (CR + PR). Complete response: Disappearance of all target lesions; Partial response: ≥ 30% decrease in the sum of the longest diameter of target lesions compared to baseline (and not ≥20% increase compared to smallest sum).

    Time frame: 6 - 8 weeks

  3. Trough Concentrations for RAD001 and for Imatinib - Phase II

    Assessed the pharmacokinetics (PK) of the combination administration of RAD001 and imatinib in this patient population.

    Time frame: Part II Daily regimen: Baseline, Days 8, 15 and thereafter approximately every two months starting at month 3 whenever possible

  4. Overall Survival (OS) - Phase I & II

    Assessed clinical efficacy of the combination regimen in this patient population per Overall Survival (OS). Overall survival was defined as the time from date of start of treatment to date of death due to any cause. For patients still receiving study medication at the time of the analysis, survival was censored at the date of last examination. If a patient was not known to have died but was no longer continuing with study medication, survival was censored at the date of last contact.

    Time frame: about 60 months

  5. 4-Month Progression-free Survival (PFS) Rate - Phase II

    Assessed clinical efficacy of the combination regimen in this patient population per Progression-free survival (PFS). Progression-free survival (PFS) was the time from date of start of treatment to the date of first documented progression or death due to any cause. Per protocol (PP) population includes patients with no known overall lesion response during 4 months +/- 2 weeks, or who later had response of CR/PR/stable disease (SD). PP population excludes patients with no known response during 4 months + / -2 weeks and no subsequent CR/PR/SD.

    Time frame: about 4 months

  6. Progression-free Survival (PFS) - Phase II

    Assessed clinical efficacy of the combination regimen in this patient population per Progression-free survival (PFS). Progression-free survival (PFS) was the time from date of start of treatment to the date of first documented progression or death due to any cause. If a patient had not progressed or died, progression-free survival was censored at the time of last adequate tumor assessment. According to the study protocol no tumor assessments were performed after discontinuation of treatment with study drug. Therefore, for all patients who discontinued treatment without a documented progression but died thereafter, death was considered as PFS event only if it occurred within the regular safety follow-up of 28 days after discontinuation. Otherwise, the PFS time was censored at the last adequate tumor assessment.

    Time frame: about 60 months

Secondary outcomes

  1. mTOR Pathway Activity Before Treatment, and Inhibition of mTOR Pathway Activity During Treatment as a Predictive Factor of Response, as Shown by Molecular Pathological Examination of the Tumor.

    assess mTOR pathway activity before treatment, and inhibition of mTOR pathway activity during treatment as a predictive factor of response, as shown by molecular pathological examination of the tumor.

    Time frame: about 60 months

  2. Relationship Between Drug-induced Changes in the Principal Molecular Marker of Intratumoral mTOR Activity and Changes in Other Molecular Markers of Tumoral Activity (e.g. Indicators of Pathway Activity, Cell Proliferation and Apoptosis).

    assess the relationship between drug-induced changes in the principal molecular marker of intratumoral mTOR activity and changes in other molecular markers of tumoral activity (e.g. indicators of pathway activity, cell proliferation and apoptosis).

    Time frame: about 60 months

  3. Relationship Between Drug-induced Changes in Tumoral Metabolism, as Shown by Functional Imaging With 18F-fluorodeoxyglucose Positron Emission Tomography (FDC-PET), With Clinical Outcome and Changes in Molecular Pathology.

    assess the relationship between drug-induced changes in tumoral metabolism, as shown by functional imaging with 18F-fluorodeoxyglucose positron emission tomography (FDC-PET), with clinical outcome and changes in molecular pathology.

    Time frame: about 60 months

07

Results

Posted Jun 25, 2021

Participant flow

This trial was a Phase I/II study, following a sequential 2-part design. The 1st part was designed to assess whether there was a pharmacokinetic interaction between Glivec/Gleevec and RAD001. The 2nd part was designed to assess the potential efficacy of the combination in Glivec/Gleevec-resistant GIST patients in 2 strata of patients.

Phase l by Treatment
Participant flow — Phase l by Treatment
MilestonePhase l: RAD001 20mg/WeekPhase l: RAD001 2.5mg/Day + Glivec 600mg/DayPhase l: RAD001 5mg/Day + Glivec 600mg/DayPhase l: RAD001 2.5mg/Day + Glivec 800mg/DayPhase ll - Stratum l (First-line Resistant/Refractory): RAD001 2.5mg/Day + Glivec 600mg/DayPhase ll: Stratum ll (Post Second-line Therapy)
Started131351100
Completed000000
Not completed131351100
Withdrew: Adverse event142300
Withdrew: Abnormal laboratory value(s)001000
Withdrew: Abnormal test procedure result(s)000100
Withdrew: Disease progression1282500
Withdrew: Withdrawal by subject000100
Withdrew: Death010100
Phase ll by Stratum
Participant flow — Phase ll by Stratum
MilestonePhase l: RAD001 20mg/WeekPhase l: RAD001 2.5mg/Day + Glivec 600mg/DayPhase l: RAD001 5mg/Day + Glivec 600mg/DayPhase l: RAD001 2.5mg/Day + Glivec 800mg/DayPhase ll - Stratum l (First-line Resistant/Refractory): RAD001 2.5mg/Day + Glivec 600mg/DayPhase ll: Stratum ll (Post Second-line Therapy)
Started00002847
Completed000001
Not completed00002846
Withdrew: Adverse event0000210
Withdrew: Abnormal laboratory values000001
Withdrew: Disease progression00002331
Withdrew: Withdrawal by subject000023
Withdrew: Death000011

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs): Phase I & II

Assessed safety and tolerability of the combination administration of RAD001 and imatinib when given to patients with imatinib-refractory gastro-intestinal stromal tumors (GIST) by number of participants with adverse events.

Time frame:
4 - 8 weeks
Reported as:
Number · Participants
Number of Participants With Adverse Events (AEs): Phase I & II
ParticipantsPhase l: RAD001 20mg/WeekPhase l: RAD001 2.5mg/Day + Glivec 600mg/DayPhase l: RAD001 5mg/Day + Glivec 600mg/DayPhase l: RAD001 2.5mg/Day + Glivec 800mg/DayPhase ll - Stratum l (First-line Resistant/Refractory): RAD001 2.5mg/Day + Glivec 600mg/DayPhase ll: Stratum ll (Post Second-line Therapy)
Number of Participants With Adverse Events (AEs): Phase I & II13135112747
PrimaryBest Overall Response (BOR) as Assessed by Overall Response (Complete Response (CR) & Partial Response (PR)) - Phase I & II

Assessed clinical efficacy of the combination regimen in this patient population per BOR by Overall response (CR + PR). Complete response: Disappearance of all target lesions; Partial response: ≥ 30% decrease in the sum of the longest diameter of target lesions compared to baseline (and not ≥20% increase compared to smallest sum).

Time frame:
6 - 8 weeks
Reported as:
Number · Percentage of Participants
Best Overall Response (BOR) as Assessed by Overall Response (Complete Response (CR) & Partial Response (PR)) - Phase I & II
Percentage of ParticipantsPhase l: RAD001 20mg/WeekPhase l: RAD001 2.5mg/Day + Glivec 600mg/DayPhase l: RAD001 5mg/Day + Glivec 600mg/DayPhase l: RAD001 2.5mg/Day + Glivec 800mg/DayPhase ll - Stratum l (First-line Resistant/Refractory): RAD001 2.5mg/Day + Glivec 600mg/DayPhase ll: Stratum ll (Post Second-line Therapy)
Best Overall Response (BOR) as Assessed by Overall Response (Complete Response (CR) & Partial Response (PR)) - Phase I & II0 (0.0 to 0.0)1 (0.2 to 36.0)0 (0.0 to 0.0)0.0 (0.0 to 0.0)0 (0.0 to 0.0)1 (0.1 to 11.3)
PrimaryTrough Concentrations for RAD001 and for Imatinib - Phase II

Assessed the pharmacokinetics (PK) of the combination administration of RAD001 and imatinib in this patient population.

Time frame:
Part II Daily regimen: Baseline, Days 8, 15 and thereafter approximately every two months starting at month 3 whenever possible
Reported as:
Median · ng/mL
Trough Concentrations for RAD001 and for Imatinib - Phase II
ng/mLPhase ll - Stratum l (First-line Resistant/Refractory): RAD001 2.5mg/Day + Glivec 600mg/DayPhase ll: Stratum ll (Post Second-line Therapy)
Week 2: RAD00124.300 (24.30 to 24.30)12.100 (5.80 to 17.20)
Week 3: RAD00119.900 (19.90 to 19.90)12.750 (7.62 to 23.30)
Week 9: RAD001—10.950 (10.40 to 11.50)
Month 4: RAD001—7.840 (6.90 to 10.30)
Baseline: Imatinib472.00 (472.0 to 472.0)501.50 (402.0 to 1210.0)
Week 2: Imatinib626.50 (549.0 to 704.0)540.00 (330.0 to 1970.0)
Week 3: Imatinib572.00 (203.0 to 590.0)718.00 (412.0 to 4040.0)
Week 9: Imatinib—899.0 (295.0 to 1780.0)
Month 4: Imatinib333.00 (333.0 to 333.0)446.00 (89.9 to 1350.0)
Month 6: Imatinib181.00 (181.0 to 181.0)2040.00 (2040.0 to 2040.0)
Month 8: Imatinib—575.00 (566.0 to 584.0)
Month 12: Imatinib—324.00 (324.0 to 324.0)
PrimaryOverall Survival (OS) - Phase I & II

Assessed clinical efficacy of the combination regimen in this patient population per Overall Survival (OS). Overall survival was defined as the time from date of start of treatment to date of death due to any cause. For patients still receiving study medication at the time of the analysis, survival was censored at the date of last examination. If a patient was not known to have died but was no longer continuing with study medication, survival was censored at the date of last contact.

Time frame:
about 60 months
Reported as:
Median · months
Overall Survival (OS) - Phase I & II
monthsPhase l: RAD001 20mg/WeekPhase l: RAD001 5mg/Day + Glivec 600mg/DayPhase l: RAD001 2.5mg/Day + Glivec 600mg/DayPhase l: RAD001 2.5mg/Day + Glivec 800mg/DayPhase ll - Stratum l (First-line Resistant/Refractory): RAD001 2.5mg/Day + Glivec 600mg/DayPhase ll: Stratum ll (Post Second-line Therapy)
Overall Survival (OS) - Phase I & II9.4 (5.6 to 13.8)10.9 (3.3 to NA)18.7 (3.8 to NA)NA (12.0 to NA)14.9 (14.9 to NA)10.7 (6.3 to 16.8)
SecondarymTOR Pathway Activity Before Treatment, and Inhibition of mTOR Pathway Activity During Treatment as a Predictive Factor of Response, as Shown by Molecular Pathological Examination of the Tumor.

assess mTOR pathway activity before treatment, and inhibition of mTOR pathway activity during treatment as a predictive factor of response, as shown by molecular pathological examination of the tumor.

Time frame:
about 60 months

No measurements were reported for this outcome.

SecondaryRelationship Between Drug-induced Changes in the Principal Molecular Marker of Intratumoral mTOR Activity and Changes in Other Molecular Markers of Tumoral Activity (e.g. Indicators of Pathway Activity, Cell Proliferation and Apoptosis).

assess the relationship between drug-induced changes in the principal molecular marker of intratumoral mTOR activity and changes in other molecular markers of tumoral activity (e.g. indicators of pathway activity, cell proliferation and apoptosis).

Time frame:
about 60 months

No measurements were reported for this outcome.

SecondaryRelationship Between Drug-induced Changes in Tumoral Metabolism, as Shown by Functional Imaging With 18F-fluorodeoxyglucose Positron Emission Tomography (FDC-PET), With Clinical Outcome and Changes in Molecular Pathology.

assess the relationship between drug-induced changes in tumoral metabolism, as shown by functional imaging with 18F-fluorodeoxyglucose positron emission tomography (FDC-PET), with clinical outcome and changes in molecular pathology.

Time frame:
about 60 months

No measurements were reported for this outcome.

Primary4-Month Progression-free Survival (PFS) Rate - Phase II

Assessed clinical efficacy of the combination regimen in this patient population per Progression-free survival (PFS). Progression-free survival (PFS) was the time from date of start of treatment to the date of first documented progression or death due to any cause. Per protocol (PP) population includes patients with no known overall lesion response during 4 months +/- 2 weeks, or who later had response of CR/PR/stable disease (SD). PP population excludes patients with no known response during 4 months + / -2 weeks and no subsequent CR/PR/SD.

Time frame:
about 4 months
Reported as:
Number · Percentage of participants
4-Month Progression-free Survival (PFS) Rate - Phase II
Percentage of participantsPhase ll - Stratum l (First-line Resistant/Refractory): RAD001 2.5mg/Day + Glivec 600mg/DayPhase ll: Stratum ll (Post Second-line Therapy)
4-Month Progression-free Survival (PFS) Rate - Phase II17.4 (5.0 to 38.8)37.1 (21.5 to 55.1)
PrimaryProgression-free Survival (PFS) - Phase II

Assessed clinical efficacy of the combination regimen in this patient population per Progression-free survival (PFS). Progression-free survival (PFS) was the time from date of start of treatment to the date of first documented progression or death due to any cause. If a patient had not progressed or died, progression-free survival was censored at the time of last adequate tumor assessment. According to the study protocol no tumor assessments were performed after discontinuation of treatment with study drug. Therefore, for all patients who discontinued treatment without a documented progression but died thereafter, death was considered as PFS event only if it occurred within the regular safety follow-up of 28 days after discontinuation. Otherwise, the PFS time was censored at the last adequate tumor assessment.

Time frame:
about 60 months
Reported as:
Median · months
Progression-free Survival (PFS) - Phase II
monthsPhase ll - Stratum l (First-line Resistant/Refractory): RAD001 2.5mg/Day + Glivec 600mg/DayPhase ll: Stratum ll (Post Second-line Therapy)
Progression-free Survival (PFS) - Phase II1.9 (1.8 to 3.7)3.5 (1.9 to 5.2)
Post-hocAll Collected Deaths

On treatment deaths were collected from FPFT up to 28 days after study drug discontinuation, for a maximum duration of 35.52 months (treatment duration ranged from 0.36 to to 35.52 months for the phase I part) and a maximum duration of 21.88 months (treatment duration of 0.16 to 21.88 months for the phase II part). Deaths post treatment survival follow up were collected after the on treatment period, up to 70 months.

Time frame:
approx. 35.52 months, approx. 70 months
Reported as:
Number · Participants
All Collected Deaths
ParticipantsPhase l: RAD001 20mg/WeekPhase l: RAD001 2.5mg/Day + Glivec 600mg/DayPhase l: RAD001 5mg/Day + Glivec 600mg/DayPhase l: RAD001 2.5mg/Day + Glivec 800mg/DayPhase ll - Stratum l (First-line Resistant/Refractory): RAD001 2.5mg/Day + Glivec 600mg/DayPhase ll: Stratum ll (Post Second-line Therapy)
Total Deaths12833922
Deaths on-treatment230236

Adverse events

Collected over On-treatment deaths were collected from FPFT up to 28 days after study drug discontinuation, for a maximum duration of 35.52 months (treatment duration ranged from 0.36 to to 35.52 months for Phase I part) and a maximum duration of 21.88 months (treatment duration of 0.16 to 21.88 months for the Phase II part).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase I - RAD001 20mg/Week ++ Glivec 600mg/Day—4/13 (30.8%)13/13 (100%)
Phase I: RAD001 2.5mg/Day + Glivec 600mg/Day—7/13 (53.8%)12/13 (92.3%)
Phase I: RAD001 5mg/Day + Glivec 600mg/Day—3/5 (60%)5/5 (100%)
Phase I: RAD001 2.5mg/Day + Glivec 800mg/Day—7/11 (63.6%)11/11 (100%)
Phase ll - Stratum l (First-line Resistant/Refractory): RAD001 2.5mg/Day + Glivec 600mg/Day—11/28 (39.3%)27/28 (96.4%)
Phase ll: Stratum ll (Post Second-line Therapy)—25/47 (53.2%)47/47 (100%)
Most frequent serious events
Showing 10 of 94
Most frequent serious events
EventPhase I - RAD001 20mg/Week ++ Glivec 600mg/DayPhase I: RAD001 2.5mg/Day + Glivec 600mg/DayPhase I: RAD001 5mg/Day + Glivec 600mg/DayPhase I: RAD001 2.5mg/Day + Glivec 800mg/DayPhase ll - Stratum l (First-line Resistant/Refractory): RAD001 2.5mg/Day + Glivec 600mg/DayPhase ll: Stratum ll (Post Second-line Therapy)
AnaemiaBlood and lymphatic system disorders2/133/132/50/111/288/47
NauseaGastrointestinal disorders0/130/132/50/110/280/47
VomitingGastrointestinal disorders1/130/132/50/111/282/47
General physical health deteriorationGeneral disorders1/131/132/50/111/281/47
Blood creatinine increasedInvestigations4/132/130/50/111/280/47
ThrombocytopeniaBlood and lymphatic system disorders0/130/131/51/110/280/47
DiarrhoeaGastrointestinal disorders1/130/131/51/111/280/47
Gastritis haemorrhagicGastrointestinal disorders0/131/131/50/110/280/47
MelaenaGastrointestinal disorders0/130/131/50/110/284/47
PneumoniaInfections and infestations0/130/131/51/110/280/47
Most frequent other events
Showing 10 of 196
Most frequent other events
EventPhase I - RAD001 20mg/Week ++ Glivec 600mg/DayPhase I: RAD001 2.5mg/Day + Glivec 600mg/DayPhase I: RAD001 5mg/Day + Glivec 600mg/DayPhase I: RAD001 2.5mg/Day + Glivec 800mg/DayPhase ll - Stratum l (First-line Resistant/Refractory): RAD001 2.5mg/Day + Glivec 600mg/DayPhase ll: Stratum ll (Post Second-line Therapy)
NauseaGastrointestinal disorders7/138/135/57/1112/2816/47
FatigueGeneral disorders9/138/132/59/1115/2816/47
Oedema peripheralGeneral disorders2/132/131/58/118/2817/47
DiarrhoeaGastrointestinal disorders8/135/132/57/1112/2817/47
AnaemiaBlood and lymphatic system disorders6/137/133/54/1112/2822/47
VomitingGastrointestinal disorders3/133/133/55/116/2814/47
PyrexiaGeneral disorders3/135/133/53/114/289/47
Weight decreasedInvestigations4/133/133/52/116/288/47
InsomniaPsychiatric disorders3/131/133/52/111/283/47
CoughRespiratory, thoracic and mediastinal disorders2/136/131/52/113/287/47

Baseline characteristics

The Intent-to-treat population (ITT-population) consists of all patients who received at least one dose of RAD001 or Glivec/Gleevec in accordance to the study protocol.

Age, Continuous
Age, Continuous(Years)Phase l: RAD001 20mg/WeekPhase l: RAD001 2.5mg/Day + Glivec 600mg/DayPhase l: RAD001 5mg/Day + Glivec 600mg/DayPhase l: RAD001 2.5mg/Day + Glivec 800mg/DayPhase ll - Stratum l (First-line Resistant/Refractory): RAD001 2.5mg/Day + Glivec 600mg/DayPhase ll: Stratum ll (Post Second-line Therapy)Total
Mean————55.6 ± 13.1659.3 ± 12.5457.9 ± 12.81
Age, Continuous
Age, Continuous(Years)Phase l: RAD001 20mg/WeekPhase l: RAD001 2.5mg/Day + Glivec 600mg/DayPhase l: RAD001 5mg/Day + Glivec 600mg/DayPhase l: RAD001 2.5mg/Day + Glivec 800mg/DayPhase ll - Stratum l (First-line Resistant/Refractory): RAD001 2.5mg/Day + Glivec 600mg/DayPhase ll: Stratum ll (Post Second-line Therapy)Total
Mean53.5 ± 5.2552.2 ± 14.1153.8 ± 11.9561.9 ± 13.25——55.3 ± 11.80
Sex: Female, Male
Sex: Female, Male(Participants)Phase l: RAD001 20mg/WeekPhase l: RAD001 2.5mg/Day + Glivec 600mg/DayPhase l: RAD001 5mg/Day + Glivec 600mg/DayPhase l: RAD001 2.5mg/Day + Glivec 800mg/DayPhase ll - Stratum l (First-line Resistant/Refractory): RAD001 2.5mg/Day + Glivec 600mg/DayPhase ll: Stratum ll (Post Second-line Therapy)Total
Female234271634
Male111019213183
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Phase l: RAD001 20mg/WeekPhase l: RAD001 2.5mg/Day + Glivec 600mg/DayPhase l: RAD001 5mg/Day + Glivec 600mg/DayPhase l: RAD001 2.5mg/Day + Glivec 800mg/DayPhase ll - Stratum l (First-line Resistant/Refractory): RAD001 2.5mg/Day + Glivec 600mg/DayPhase ll: Stratum ll (Post Second-line Therapy)Total
Caucasian13125112747115
Black0100102
08

Study locations

16 sites
  • Dana Farber Cancer Institute Dept of Sarcoma Oncology
    Boston, Massachusetts 02215, United States
  • College of Physicians and Surgeons of Columbia University
    New York, New York 10032, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • Novartis Investigative Site
    Edegem, Antwerpen 2650, Belgium
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Bordeaux, 33076, France
  • Novartis Investigative Site
    Lille Cedex, 59020, France
  • Novartis Investigative Site
    Lyon, F-69373, France
  • Novartis Investigative Site
    Marseille Cedex 05, 13385, France
  • Novartis Investigative Site
    Villejuif Cedex, 94805, France
  • Novartis Investigative Site
    Berlin, 13125, Germany
  • Novartis Investigative Site
    Frankfurt, 60488, Germany
  • Novartis Investigative Site
    Hamburg, 20246, Germany
  • Novartis Investigative Site
    Koeln, 50937, Germany
  • Novartis Investigative Site
    Muenchen, 81377, Germany
  • Novartis Investigative Site
    Tübingen, 72076, Germany
09

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the triasl in line with applicable laws and regulations. This trial data will be available according to the process described on www.clinicalstudydatarequest.com.

Data sharing details ↗ · www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2002 to primary completion in Sep 2008, 69 months.

Results were first posted in Jun 2021, 12 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2011
First posted
Jan 12, 2011
StartActual
Nov 13, 2002
Primary completionActual
Sep 3, 2008
CompletionActual
Sep 3, 2008
Results first posted
Jun 25, 2021
Last update
Jun 25, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01275222
Responsible party
Sponsor
First posted
Jan 12, 2011
Start date
Nov 13, 2002
Primary completion
Sep 3, 2008
Completion
Sep 3, 2008
Results posted
Jun 25, 2021
Last update
Jun 25, 2021

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Everolimus

Start the discussion